Dupilumab (Dupixent; Sanofi and Regeneron) is safe and effective for treating atopic dermatitis (AD) in pediatric patients, according to a recent review.
Studies have shown that dupilumab is safe and effective for pediatric use, but proper real-world analysis of dupilumab use has not been recorded.
To determine the long-term efficacy of dupilumab, the researchers collected medical records from March 2017 to September 2022 from pediatric patients with moderate to severe AD.
Information was collected on patient demographics, body surface area (BSA), index of eczema area and severity (EASI), and Investigator’s Global Assessment (IGA).
Nearly 90 patients were followed, and all saw a 75% improvement in EASI after at least 1 year of dupilumab use, with approximately 60% of patients seeing a 90% improvement.
Improvements were also observed in BSA and IGA. Patients with a positive history of atopy saw a greater improvement in BSA from weeks 12 to 24.
Adverse events were observed in approximately 14% of patients, with the most common being conjunctivitis and arthralgia. No serious adverse events were observed.
Pagan AD, David E, Ungar B, Ghalili S, He H, Guttman-Yassky E. J Allergy Clinic Immunol Pract. 2022;10(9):2378-2385. doi: 10.1016/j.jaip.2022.06.014